BioTuesdays

Category - Markets

AVEO Pharmaceuticals Logo
Markets

HCW cuts AVEO Pharma to neutral; PT to $1 from $9

H.C. Wainwright downgraded AVEO Pharmaceuticals (NASDAQ:AVEO) to “neutral” from “buy” and slashed its price target to $1 from $9 after the FDA recommended against the filing of a tivozanib NDA, citing the lack of...

February 1, 2019
Mesoblast Logo
Markets

HCW assumes coverage of Mesoblast at buy; PT $6.50

H.C. Wainwright analyst Swayampakula Ramakanth assumed coverage of Mesoblast (NASDAQ:MESO) with a “buy” rating and price target of $6.50. The stock closed at $4.56 on Jan. 30. Australia-based Mesoblast is focused on...

January 31, 2019
scPharmaceuticals
Markets

Leerink cuts scPharma to MP; PT to $5 from $12

Leerink downgraded scPharmaceuticals (NASDAQ:SCPH) to “market perform” from “outperform” and slashed its price target to $5 from $12 after the company inked a deal to use West Pharmaceuticals’ SmartDose on-body drug...

January 30, 2019
Evolus
Markets

Stifel starts Evolus at buy; PT $27

Stifel launched coverage of Evolus (NASDAQ:EOLS) with a “buy” rating and 12-month price target of $27. The stock closed at $14.99 on Jan. 28. “Evolus’ success hinges on the potential for Jeuveauto serve as an...

January 29, 2019
Revance
Markets

Stifel starts Revance Therapeutics at buy; PT $50

Stifel initiated coverage of Revance Therapeutics (NASDAQ:RVNC) with a “buy” rating and $50 target price. The stock closed at $17 on Jan. 28. Revance’s Daxi product represents “one of the first truly novel neurotoxin...

January 29, 2019
IsoRay
Markets

HCW assumes coverage of IsoRay at buy; PT 70 cents

H.C. Wainwright analyst Swayampakula Ramakanth assumed coverage of IsoRay (NYSE American:ISR) with a “buy” rating and price target of 70 cents, saying the company is “at an inflection point of sustainable revenue growth...

January 28, 2019
AzurRx BioPharma
Markets

Roth starts AzurRx BioPharma at buy; PT $10.50

Roth Capital Partners launched coverage of AzurRx BioPharma (NASDAQ:AZRX) with a “buy” rating and price target of $10.50. The stock closed at $2.25 on Jan. 25. AzurRx is developing non-systemic, recombinant enzyme...

January 28, 2019
Bellerophon Therapeutics
Markets

Maxim starts Bellerophon Therapeutics at buy; PT $3

Maxim Group initiated coverage of Bellerophon Therapeutics (NASDAQ:BLPH) with a “buy” rating and $3 price target. The stock closed at 67 cents on Jan. 23. Bellerophon’s lead product is the INOpulse delivery system of...

January 24, 2019